Omeros receives rare pediatric disease designation for zaltenibart from FDA

Omeros announced that zaltenibart has received rare pediatric disease designation from the FDA for the treatment of complement 3 glomerulopathy, or C3G, an ultra-rare, progressive renal disorder primarily afflicting children [...]